Introduction
Nanoparticle based therapeutics obviously has an intrinsic potential to bring a major shift in the landscape of the pharmaceutical industry. [1] [2] [3] Evidently, scores of nanobased medicine have been approved by the US Food and Drug Administration (FDA) for clinical use, and many more are in clinical or preclinical pipelines. 4, 5 Liposomes, 6 polymers, 7 dendrimers, 8 carbon nanotubes, 9 gold 10 and magnetic nanoparticle11 based therapeutics are few of the widely explored nanocarriers to increase the efficacy of various anticancer drugs due to enhanced permeability and retention (EPR) effect of cancer tissues. Furthermore, different pathophysiological conditions and ligand carrying capabilities of nanocarriers also ensured target specific intratumoral drug accumulation. Among these libraries of sophisticated nanocarriers, mesoporous silica nanoparticles (MSN) have recently emerged as a promising nanoplatform to engineer a wide array of therapeutic and diagnostic nanoconstructs. 12, 13 In particular, considering the stimuli responsive drug delivery, mesoporous silica has proved its niche in this realm, due to the presence of well-defined nanochannels and outer surface which can be manipulated to accommodate different environmental conditions. Using this concept of gate keeping, several research groups have attempted to design different stimuli responsive nanosystem to inhibit the premature release of cytotoxic drugs. To manipulate diverse kinds of capping entities, both external and internal triggers such as pH, [14] [15] [16] redox, [17] [18] [19] [20] light, 21, 22 enzymes, 23 magnetic, 24 electric field and competitive binding, 25 have been employed to regulate the release of cytotoxic molecules according to environmental requirements. In this respect, our group has recently reported a pH responsive nanovehicle by use of the acid sensitive nature of ZnO quantum dots to release an anticancer drug from mesopores. 26 Besides stimuli responsive drug delivery, there has also been an overwhelming research interest in the development of theranostic nanomaterials for simultaneous imaging and therapy. In view of that, diverse kinds of biological imaging agents have been incorporated into mesoporous silica, to realize X-ray computed tomography (CT) 27 , fluorescence, 28 near IR (NIR)29, and magnetic resonance imaging (MRI). [30] [31] [32] Currently, MRI is one of the most dominant in vivo imaging technologies; however clinically, to improve the quality of image, contrast enhancement agents are used to increase the signal difference between the area of concern and the background. In the last few years, Hyeon's research group reported several studies that incorporated MRI agents into mesoporous silica. [33] [34] [35] Recently, they have fabricated a core
shell MnO@MSN nanostructure for labelling stem cells. 35 Very recently, manganese oxides based nanoparticles has been developed as T1 contrast agents for MRI signal enhancement .36, 37 Despite this phenomenal research activity in nanotheranostics, more specific and precise manipulation are needed to not only achieve stimuli responsive drug release, but also improve the quality of imaging for better diagnosis or subsequent feedback of chemotherapy. Till now, numerous redox responsive systems have been developed for intracellular release of several therapeutic entities, by using widely known reducing agents such as dithiothreitol (DTT), mercaptoethanol and glutathione (GSH). 17, 18 Mechanistically, the cleavage of disulphide bond has been a sole option in all previously reported redox responsive system to uncap the nanochannels. Through a paramagnetic nanolid dissolution strategy, instead of disulphide bond cleavage, herein we developed an intelligent dual-purpose nanocarrier to achieve both simultaneous therapy and MRI. Fig. 1 ). Moreover, mesoporous surface tethered redox-sensitive Mn 3 O 4 nanocrystals simultaneously served as nanolids and provided an opportunity for enhanced MR images due to the presence of free Mn(II) ions released after the dissolution of nanolids. Sigma-Aldrich. The morphologies and detailed structure of the samples were recorded using JEOL JSM-6700F field-emission scanning electron microscope (SEM) and FEI Tecnai G2 F20 S-TWIN transmission electron microscope (TEM). The powder XRD patterns were recorded on a Rigaku D/Ma 2550 X-ray diffractometer with Cu-Kα radiation (λ = 1.5418 Å). Fourier transform infrared (FTIR) spectra were collected on a Nicolet Impact 410 FTIR spectrometer in the range of 400 -4000 cm−1. Elemental analysis was carried out on Perkin-Elmer ICP-OES Optima 3300DV. X-ray photoelectron spectroscopy (XPS) was performed using an ESCALAB 250 spectrometer. Raman spectra were obtained with a Renishaw Raman system model 1000 spectrometer.
Experimental

Materials and instrumentation
Synthesis of water dispersible Mn 3 O 4 nanocrystals
Mn 3 O 4 nanocrystals were synthesized by a facile hydrothermal method, using Mn(CH 3 COOH)2·4H 2 O as manganese source. First of all, Mn(CH 3 COOH) 2 ·4H 2 O (10 mmol) was dissolved in 70 mL N,N-dimethylformamide (DMF). Then, the transparent solution was transferred into Teflon-lined autoclave and heated at 160 °C for 8 h, cooled down to room temperature naturally. After the synthesis of Mn 3 O 4 nanocrystal, they were rendered water soluble by functionalization with amine moiety. The assynthesized transparent solution of Mn 3 O 4 was transferred into a round bottom flask and temperature was raised to 130 °C, followed by the addition of 500 µL of APTES. The resulting brownish precipitate was afterwards centrifuged and washed with ethanol, dried in air.
Synthesis and modification of MSN
MSN was prepared as described previously. 0.5 g of CTAB was first dissolved in 240 mL deionized water. Sodium hydroxide aqueous solution (2M, 1.8 mL) was added to the CTAB solution, and then the reaction temperature was raised to 80 °C. After stabilizing the temperature, TEOS (2.5 mL, 11.2 mmol) was added drop wise to the surfactant solution and held the reaction mixture for 2 h to give a white precipitate. The solid product was filtered, washed with deionized water and ethanol, dried at 60 °C to yield the as-synthesized MSN. The surface of as-synthesized MSN was functionalized with carboxyl groups to ensure capping by treatment as follows. As-synthesized MSN (300 mg) was refluxed for 12 h in 20 mL anhydrous toluene, containing 300 µL APTES, to functionalize amine group. After centrifugation and washing with ethanol, aminefunctionalized MSN was redispersed in 20 mL of DMSO with succinic anhydride (100 mg) and triethylamine (100 µL) and stirred at 50 °C for 24 h to yield the MSN-COOH. To remove the template (CTAB), the MSN-COOH was refluxed for 6 h in acidic methanolic solution.
Loading, capping and release experiments
Typically, blank MSN-COOH powder (50 mg) was dispersed into 1 mL DMSO, containing 10 mg CPT, and stirred at room temperature for overnight to load hydrophobic drug. The solution was then centrifuged and dispersed in water and further stirred for 6 h, followed by addition of 25 mg EDC·HCl and 200 mg Mn 3 O 4 nanocrystals (dispersed in water). The mixture was stirred for another 10 min. The precipitate was centrifuged, it was then dialyzed (molecular weight cut-off = 8 kDa) against distilled water for 2 days to remove the CPT from uncapped nanochannels. All the washings including before capping were collected to calculate the final loading amount. To investigate the redox-responsive properties of Mn 3 O 4 @MSN@CPT formulation, 5 mg sample was first dispersed in 5 mL of PBS with different concentration of GSH or DTT, then put in a dialysis bags and dialyzed against 45 mL of respective solutions in outside vial. The released quantity of CPT was collected at predetermined time intervals and analyzed by UV/Vis spectroscopy at 365 nm.
Cell culture and in vitro cell viability assay
Pancreatic cancer cells (BxPC-3) were grown in monolayer in Dulbecco's Modified Eagle's Medium (DMEM, Gibco) supplemented with 5% (v/v) fetal bovine serum (FBS, Gibco) and penicillin/streptomycin (100 U/ml and 100 µg/ml, respectively, Gibco) in a humidified 5% CO 2 atmosphere at 37 °C. Cell viability was investigated by measuring the ability of cells to transform MTT to a purple formazan dye. For MTT assay, BxPC-3 cells were seeded into 96-well plates at a density of 8*10 3 cells per well in 100 µL of media and grown overnight. 
Results and discussion
MCM-41-based MSN were synthesized via sol-gel chemistry. 38 The MSN material was then surface-functionalized with carboxylic groups to ensure capping of drug loaded nanochannels (denoted as MSN-COOH). Poorly water-soluble antitumor drug (camptothecin, CPT) was selected as the model drug and loaded into the pores of MSN, and the loading amount was significantly high (53.2 mg/g) compared to those reported in previous studies. 12 Meanwhile, manganese oxide nanolids were prepared using a really facile route. Otherwise, hightemperature methods are routinely used to synthesize hydrophobic nanoparticles in the presence of organic surfactants and solvents.
39, 40
However, hydrophobic nanoparticles thus obtained require tedious and time-consuming ligand exchange approaches to render them water dispersible In this work, no organic capping ligands were needed in the course of synthesis. After treating Mn 3 O 4 with 3-aminopropyltriethoxysilane (APTES), a transparent aqueous solution of amine-functionalized Mn 3 O 4 nanolids (Mn 3 O 4 -NH 2 ) was obtained. The resulting nanolids were subsequently used to cap CPT loaded MSN-COOH orifices via EDC chemistry, in order to minimize the premature release of a cytotoxic drug. Addition of gate-opening triggers, reducing agents such as GSH or DTT, would then uncap the mesopores by redox assisted dissolution of Mn 3 O 4 , allowing the release of the drug molecules. To investigate this capped system, scanning electron microscopy (SEM) and transmission electron microscopy (TEM) techniques were first used to determine the interaction between MSN and Mn 3 O 4 nanocrystals. MSN showed smooth surfaces with diameters of ~100 nm in SEM micrograph, whereas 2 nm wide channels were visible in TEM images (Supporting Information Fig. S1a, b) . The particle size of Mn 3 O 4 -NH 2 nanocrystals was found to be in 5-7nm range (Supporting Information Fig. S2 ). After capping, CPT loaded Mn 3 O 4 @MSN nanocarriers acquired a scabrous surface compared to original MSN, as evidenced from both SEM and TEM micrographs due to the presence of studded dark spots, which blocked the nanochannels (Fig. 2a, b, c, d ).
Small and wide angle X-ray diffraction (XRD) analysis is performed to validate the drug loading and pore capping procedures. The intensity of characteristic MCM-41type peak is markedly reduced in drug loaded and Mn 3 O 4 conjugated nanocarrier (Mn 3 O 4 @MSN@CPT) due to the contrast and disordered product (Fig. 3f) . Figure 3e indicates characteristics peaks of Mn 3 O 4 , the broadness of these peaks can be ascribed to ultrasmall particles size of desired nanolids. Moreover, crystallite size is determined by using Scherer equation. According to XRD data the crystallite size is found to be 7.4 nm. XRD results also validate the conjugation of Mn 3 O 4 onto the surface of MSN in terms of reduction in the intensity of characteristics Mn 3 O 4 peaks. X-ray photoelectron spectroscopy (XPS) shed some light on Mn 3 O 4 and MSN conjugation. In the survey region (0−1200 eV), carbon, nitrogen, manganese, silicon and nitrogen elements were identified. Since Mn 3 O 4 nanoparticles are comprised of manganous and manganic ions, so deconvulation of Mn peak provides two typical peaks at 652.9 and 641.1 eV, which are ascribed to Mn 2p 1/2 and Mn 2p 3/2 spin-orbit states of Mn 3 O 4 . Energy-dispersive spectroscopy (EDS) also confirms capping of drug loaded nanochannels through Mn 3 O 4 nanolids. (Fig. S3) . Mn 3 O 4 -NH 2 nanocrystals were characterized by Infra-red (IR) (Fig. S4) . Since nitrogen adsorption analysis is usually used to evaluate material in terms of surface area and pore volume, therefore, we have carried out nitrogen adsorption−desorption study to determine the effect of drug loading and pore capping on surface area (Fig. S5) , 0.42 cc/g respectively. This study is particularly interesting in term of reductioninduced dissolution of paramagnetic nanolids from the surface of drug loaded mesopores. GSH is a common reducing agent within cells. However, compared to those in normal tissue, GSH levels in human cancer tissues such as breast, [41] [42] [43] As a proof-of-concept study to validate reduction induced dissolution of paramagnetic "gatekeeper", we dispersed Mn 3 O 4 @MSN@CPT or Mn 3 O 4 nanocrystals in phosphatebuffered saline (PBS) solution containing DTT and GSH at various concentrations (Fig. 4a, b) . Notably, these in vitro experiments furnishes an opprotunity to gain some insight about the dissolution control drug release mechanism, moreover, we can predict a similar in vivo drug release behavior after redox mediated dissoluion of magnetic nanolids. In the absence of any reducing agents, a flat baseline was obtained, and less than 6 % CPT was leached from drug formulation. In contrast, with the introduction of DTT or GSH of different amounts, CPT release profile displayed an obvious increasing trend, suggesting the dissolution of Mn 3 O 4 to unleash the loaded drug molecules. The dissolution process of Mn 3 O 4 was also verified by the gradual disappearance of the dark dots from MSN surface as revealed in TEM images (Fig. 2e, f and Supporting Information Fig. S1a,b) . Incubation of capped sample in the presence of reducing agents of different kinds and concentrations led to a more revealing and convincing proof of Mn 3 O 4 disintegration. Significant fading of dark brown colour of Mn 3 O 4 was observed along with increasing time and concentration of GSH (Fig. 4c) . To further evaluate our hypothesis of redox-induced dissolution, inductively coupled plasma (ICP) analysis was carried out to detect the concentration of manganese ions after subjecting Mn 3 O 4 to different concentration of GSH (Fig. 4d) . It was found that there was no manganese ions leached out within 12 h in the absence of GSH treatment. However, treatment of Mn 3 O 4 nanocrystals with GSH resulted in increasing concentration of manganese ions, which lend strong support to our proposed ideas that manganese ions leached from Mn 3 O 4 into liquid phase gradually. In order to assess the biological properties of our capping system, MTT assay was performed by using pancreatic cancer cells (BxPC-3) (Fig. 6a, b, c) . nanocrystals. The improvement of the cell inhibitory performance of hydrophobic CPT should be credited to hydrophilic mesoporous nanocarriers which not only ensured the controlled release of water insoluble CPT, but also realized a highly needed site specific targeted drug release.
To visualize in vitro dissolution and encapsulated cargo release, confocal microscopy was checked by loading rhodamine 6G as a model dye. Fig. 6d Fig. 7e . In comparison with pre-contrast images, an obvious signal enhancement both in kidney and liver was noticed with increasing time, indicating the potential utility of our strategy. 
Conclusions
In conclusion, we have developed a sophisticated nanotheranostic system, using Mn 3 O 4 nanoparticles to cap drug loaded channels of mesoporous silica for simultaneously performing intelligent drug delivery and redox-activated contrast-enhanced MRI. Manganese oxide nanoparticles are demonstrated to be highly susceptible to intracellular redox environment, and readily undergo dissolution when exposed to highly prevalent intracellular reducing agent glutathione. As a result, channels of silica are opened to release loaded drug molecules, leading to target specific therapeutic response against cancer cells. Most prominently, redox assisted dissolution of Mn 3 O 4 nanolids to manganese ions also led to twofold increase in T1 signal. We envision that our results would prove a significant step in personalized medicine and provide a synergistic strategy to enhance therapeutic and imaging efficiency.
